AB 1774, as amended, Bonilla. Clinical laboratories: licensure.
Existing federal law, the Clinical Laboratory Improvement Amendments of 1988 (CLIA) requires the federal Centers for Medicare and Medicaid Services to certify and regulate clinical laboratories that perform testing on humans. Complaints against individual laboratories are directed to the state.
Existing law provides for the licensure, registration, and regulation of clinical laboratories and various clinical laboratory personnel by the State Department of Public Health. Under existing law the department inspects clinical laboratories and assesses a fee for licensure of those facilities.
This bill would repeal the laws requiring a clinical laboratory to be licensedbegin delete and inspectedend delete by the department, including the licensingbegin delete fee.end deletebegin insert
fee, and would recast the inspection role of the department to involve inspection and monitoring of specified issues for clinical laboratories that are not accredited by an accrediting organization approved under CLIA, investigation upon complaint, and sanctions, as provided.end insert The bill would also make conforming changes.
Vote: majority. Appropriation: no. Fiscal committee: yes. State-mandated local program: no.
The people of the State of California do enact as follows:
Section 654.1 of the Business and Professions
2Code is amended to read:
(a) A person licensed under Chapter 4 (commencing
4with Section 1600) of this division or licensed under Chapter 5
5(commencing with Section 2000) of this division or licensed under
6any initiative act referred to in this division relating to osteopaths
7may not refer patients, clients, or customers to a clinical laboratory
8in which the licensee has a membership, proprietary interest, or
9coownership in any form, or has a profit-sharing arrangement,
10unless the licensee at the time of making the referral discloses in
11writing the interest to the patient, client, or customer. The written
12disclosure shall indicate that the patient may choose any clinical
13laboratory for purposes of having laboratory work or assignment
14performed.
15(b) This does shall not apply to persons who
are members of a
16medical group that contracts to provide medical care to members
17of a group practice prepayment plan registered under the
18Knox-Keene Health Care Service Act of 1975 (Chapter 2.2
19(commencing with Section 1340) of Division 2 of the Health and
20Safety Code).
21(c) This does shall not apply to a referral to a clinical laboratory
22that is owned and operated by a health facility licensed pursuant
23to Chapter 2 (commencing with Section 1250) of Division 2 of
24the Health and Safety Code.
25(d) This section does not prohibit the acceptance of evaluation
26specimens for proficiency testing or referral of specimens or the
27assignment from one clinical laboratory to another clinical
28laboratory, either licensed or exempt under this chapter, providing
29the report indicates clearly the laboratory performing the test.
P3 1(e) “Proprietary interest” does not include ownership of a
2building where space is leased to a clinical laboratory at the
3prevailing rate under a straight lease arrangement.
4(f) A violation of this section is a public offense and is
5punishable upon a first conviction by imprisonment in a county
6jail for not more than one year, or by imprisonment pursuant to
7subdivision (h) of Section 1170 of the Penal Code, or by a fine not
8exceeding ten thousand dollars ($10,000), or by both that
9imprisonment and fine. A second or subsequent conviction shall
10be punishable by imprisonment pursuant to subdivision (h) of
11Section 1170 of the Penal Code.
Section 655.5 of the Business and Professions Code
13 is amended to read:
(a) It is unlawful for a person licensed under this
15division or under an initiative act referred to in this division, or a
16clinical laboratory, or a health facility when billing for a clinical
17laboratory of the facility, to charge, bill, or otherwise solicit
18payment from a patient, client, or customer for a clinical laboratory
19service not actually rendered by the person or clinical laboratory
20or under his, her or its direct supervision unless the patient, client,
21or customer is apprised at the first time of the charge, billing, or
22solicitation of the name, address, and charges of the clinical
23laboratory performing the service. The first written charge, bill,
24or other solicitation of payment shall separately set forth the name,
25address, and charges of the clinical laboratory concerned and shall
26clearly show whether or not the
charge is included in the total of
27the account, bill, or charge. This subdivision is satisfied if the
28required disclosures are made to the third-party payer of the patient,
29client, or customer. If the patient is responsible for submitting the
30bill for the charges to the third-party payer, the bill provided to
31the patient for that purpose shall include the disclosures required
32by this section. This subdivision does not apply to a clinical
33laboratory of a health facility or a health facility when billing for
34a clinical laboratory of the facility nor to a person licensed under
35this division or under any initiative act referred to in this division
36if the standardized billing form used by the facility or person
37requires a summary entry for all clinical laboratory charges. For
38purposes of this subdivision, “health facility” has the same meaning
39as defined in Section 1250 of the Health and Safety Code.
P4 1(b) A clinical laboratory shall provide to each
of its referring
2providers, upon request, a schedule of fees for services provided
3to patients of the referring provider. The schedule shall be provided
4within two working days after the clinical laboratory receives the
5request. For the purposes of this subdivision, a “referring provider”
6means a provider who has referred a patient to the clinical
7laboratory in the preceding six-month period. A clinical laboratory
8that provides a list of laboratory services to a referring provider
9or to a potential referring provider shall include a schedule of fees
10for the laboratory services listed.
11(c) It is also unlawful for a person licensed under this division
12or under any initiative act referred to in this division to charge
13additional charges for a clinical laboratory service that is not
14actually rendered by the licensee to the patient and itemized in the
15charge, bill, or other solicitation of payment. This section shall not
16be construed to prohibit any
of the following:
17(1) An itemized charge for a service actually rendered to the
18patient by the licensee.
19(2) A summary charge for services actually rendered to a patient
20by a health facility, as defined in Section 1250 of the Health and
21Safety Code, or by a person licensed under this division or under
22any initiative act referred to in this division if the standardized
23billing form used by the facility or person requires a summary
24entry for all clinical laboratory charges.
25(d) As used in this section, the term “a person licensed under
26this division” includes a registered laboratory, as defined in Section
271206, all wholly owned subsidiaries of the person, a parent
28company that wholly owns the person, and any subsidiaries wholly
29owned by the same parent that wholly owns the person. “Wholly
30owned” means ownership
directly or through one or more
31subsidiaries. This section shall not apply to billings by a registered
32laboratory when the registered laboratory bills for services
33performed by a laboratory owned or operated by the registered
34laboratory.
35(e) This section does not apply to a person or clinical laboratory
36who or which contracts directly with a health care service plan
37licensed pursuant to Section 1349 of the Health and Safety Code,
38if the services are to be provided to members of the plan on a
39prepaid basis and without additional charge or liability on account
40thereof.
P5 1(f) A violation of this section is a public offense and is
2punishable upon a first conviction by imprisonment in a county
3jail for not more than one year, or by imprisonment pursuant to
4subdivision (h) of Section 1170 of the Penal Code, or by a fine not
5exceeding ten thousand dollars ($10,000), or by both that
6
imprisonment and fine. A second or subsequent conviction is
7punishable by imprisonment pursuant to subdivision (h) of Section
81170 of the Penal Code.
9(g) (1) Notwithstanding subdivision (f), a violation of this
10section by a physician and surgeon for a first offense shall be
11subject to the exclusive remedy of reprimand by the Medical Board
12of California if the transaction that is the subject of the violation
13involves a charge for a clinical laboratory service that is less than
14the charge would have been if the clinical laboratory providing
15the service billed a patient, client, or customer directly for the
16clinical laboratory service, and if that clinical laboratory charge is
17less than the charge listed in the clinical laboratory’s schedule of
18fees pursuant to subdivision (b).
19(2) This subdivision does not permit a physician and surgeon
20to charge more than he
or she was charged for the laboratory
21service by the clinical laboratory providing the service unless the
22additional charge is for service actually rendered by the physician
23and surgeon to the patient.
Section 1206 of the Business and Professions Code is
25amended to read:
(a) For the purposes of this chapter the following
27definitions are applicable:
28(1) “Analyte” means the substance or constituent being
29measured, including, but not limited to, glucose, sodium, or
30theophylline, or any substance or property whose presence or
31absence, concentration, activity, intensity, or other characteristics
32are to be determined.
33(2) “Biological specimen” means any material that is derived
34from the human body.
35(3) “Blood electrolyte analysis” means the measurement of
36electrolytes in a blood specimen by means of ion selective
37electrodes on instruments specifically designed and manufactured
38for blood gas and acid-base
analysis.
P6 1(4) “Blood gas analysis” means a clinical laboratory test or
2examination that deals with the uptake, transport, and
3metabolization of oxygen and carbon dioxide in the human body.
4(5) “Clinical laboratory test or examination” means the
5detection, identification, measurement, evaluation, correlation,
6monitoring, and reporting of any particular analyte, entity, or
7substance within a biological specimen for the purpose of obtaining
8scientific data that may be used as an aid to ascertain the presence,
9progress, and source of a disease or physiological condition in a
10human being, or used as an aid in the prevention, prognosis,
11monitoring, or treatment of a physiological or pathological
12condition in a human being, or for the performance of
13nondiagnostic tests for assessing the health of an individual.
14(6) “Clinical laboratory science” means any of the sciences or
15scientific disciplines used to perform a clinical laboratory test or
16examination.
17(7) “Clinical laboratory practice” means the application of
18clinical laboratory sciences or the use of any means that applies
19the clinical laboratory sciences within or outside of a licensed or
20registered clinical laboratory. Clinical laboratory practice includes
21consultation, advisory, and other activities inherent to the
22profession.
23(8) “Clinical laboratory” means a place used, or an establishment
24or institution organized or operated, for the performance of clinical
25laboratory tests or examinations or the practical application of the
26clinical laboratory sciences. That application may include any
27means that applies the clinical laboratory sciences.
28(9) “Direct
and constant supervision” means personal
29observation and critical evaluation of the activity of unlicensed
30laboratory personnel by a physician and surgeon, or by a person
31licensed under this chapter other than a trainee, during the entire
32time that the unlicensed laboratory personnel are engaged in the
33duties specified in Section 1269.
34(10) “Direct and responsible supervision” means both of the
35following:
36(A) Personal observation and critical evaluation of the activity
37of a trainee by a physician and surgeon, or by a person licensed
38under this chapter other than a trainee, during the entire time that
39the trainee is performing clinical laboratory tests or examinations.
P7 1(B) Personal review by the physician and surgeon or the licensed
2person of all results of clinical laboratory testing or examination
3performed by the
trainee for accuracy, reliability, and validity
4before the results are reported from the laboratory.
5(11) “Licensed laboratory” means a clinical laboratory licensed
6pursuant to the federal Clinical Laboratory Improvement
7Amendments of 1988 (CLIA).
8(12) “Location” means either a street and city address, or a site
9or place within a street and city address, where any of the clinical
10laboratory sciences or scientific disciplines are practiced or applied,
11or where clinical laboratory tests or examinations are performed.
12(13) “Physician office laboratory” means a clinical laboratory
13that is either: (A) owned and operated by a partnership or
14professional corporation that performs clinical laboratory tests or
15examinations only for patients of five or fewer physicians and
16surgeons or podiatrists who are shareholders,
partners, or
17employees of the partnership or professional corporation that owns
18and operates the clinical laboratory; or (B) owned and operated
19by an individual licensed physician and surgeon or a podiatrist,
20and that performs clinical laboratory tests or examinations only
21for patients of the physician and surgeon or podiatrist who owns
22and operates the clinical laboratory.
23(14) “Point-of-care laboratory testing device” means a portable
24laboratory testing instrument to which the following applies:
25(A) It is used within the proximity of the patient for whom the
26test or examination is being conducted.
27(B) It is used in accordance with the patient test management
28system, the quality control program, and the comprehensive quality
29assurance program established and maintained by the laboratory
30pursuant to paragraph (2) of
subdivision (d) of Section 1220.
31(C) It meets the following criteria:
32(i) Performs clinical laboratory tests or examinations classified
33as waived or of moderate complexity under the federal Clinical
34Laboratory Improvement Amendments of 1988 (CLIA) (42 U.S.C.
35Sec. 263a).
36(ii) Performs clinical laboratory tests or examinations on
37biological specimens that require no preparation after collection.
38(iii) Provides clinical laboratory tests or examination results
39without calculation or discretionary intervention by the testing
40personnel.
P8 1(iv) Performs clinical laboratory tests or examinations without
2the necessity for testing personnel to perform calibration or
3maintenance, except resetting
pursuant to the manufacturer’s
4instructions or basic cleaning.
5(15) “Public health laboratory” means a laboratory that is
6operated by a city or county in conformity with Article 5
7(commencing with Section 101150) of Chapter 2 of Part 3 of
8Division 101 of the Health and Safety Code and the regulations
9adopted thereunder.
10(16) “Registered laboratory” means a clinical laboratory that
11performs clinical laboratory tests or examinations subject to a
12certificate of waiver or a certificate of provider-performed
13microscopy under CLIA.
14(17) “Specialty” means histocompatibility, microbiology,
15diagnostic immunology, chemistry, hematology,
16immunohematology, pathology, genetics, or other specialty
17specified by regulation adopted by the department.
18(18) “Subspecialty”
for purposes of microbiology, means
19bacteriology, mycobacteriology, mycology, parasitology, virology,
20molecular biology, and serology for diagnosis of infectious
21diseases, or other subspecialty specified by regulation adopted by
22the department; for purposes of diagnostic immunology, means
23syphilis serology, general immunology, or other subspecialty
24specified by regulation adopted by the department; for purposes
25of chemistry, means routine chemistry, clinical microscopy,
26endocrinology, toxicology, or other subspecialty specified by
27regulation adopted by the department; for purposes of
28immunohematology, means ABO/Rh Type and Group, antibody
29detection for transfusion, antibody detection nontransfusion,
30antibody identification, compatibility, or other subspecialty
31specified by regulation adopted by the department; for pathology,
32means tissue pathology, oral pathology, diagnostic cytology, or
33other subspecialty specified by regulation adopted by the
34department; for purposes of genetics, means molecular biology
35
related to the diagnosis of human genetic abnormalities,
36cytogenetics, or other subspecialty specified by regulation adopted
37by the department.
38(b) This chapter does not restrict, limit, or prevent a person
39licensed to provide health care services under the laws of this state,
40including, but not limited to, licensed physicians and surgeons and
P9 1registered nurses, from practicing the profession or occupation for
2which he or she is licensed.
3(c) This chapter does not authorize a person to perform or order
4health care services, or utilize the results of the clinical laboratory
5test or examination, unless the person is otherwise authorized to
6provide that care or utilize the results. The inclusion of a person
7in Section 1206.5 for purposes of performing a clinical laboratory
8test or examination shall not be interpreted to authorize a person,
9who is not otherwise authorized, to perform
venipuncture, arterial
10puncture, or skin puncture.
Section 1206.6 of the Business and Professions Code
12 is amended to read:
Subdivision (a) of Section 1206.5 does not apply to a
14pharmacist at a community pharmacy who, upon customer request,
15performs only blood glucose, hemoglobin A1c, or cholesterol tests
16that are classified as waived under CLIA and are approved by the
17federal Food and Drug Administration for sale to the public without
18a prescription in the form of an over-the-counter test kit, provided
19that all of the following requirements are satisfied:
20(a) The pharmacy obtains a valid CLIA certificate of waiver
21and complies with all other requirements for the performance of
22waived clinical laboratory tests under applicable federal
23regulations. For purposes of CLIA, the person identified as
24responsible for directing and supervising testing oversight and
25decisionmaking shall be the pharmacist-in-charge, as
defined in
26Section 4036.5.
27(b) The pharmacy complies with this chapter.
28(c) The tests are performed only by a pharmacist, as defined in
29Section 4036, in the course of performing routine patient
30assessment procedures in compliance with Section 4052.4.
Section 1220 of the Business and Professions Code is
32amended to read:
(a) (1) Each clinical laboratory shall maintain records,
34equipment, and facilities that are adequate and appropriate for the
35services rendered.
36(2) (A) Except for tests or examinations classified as waived
37under CLIA, each clinical laboratory shall enroll, and demonstrate
38successful participation, as defined under CLIA, for each specialty
39and subspecialty in which it performs clinical laboratory tests or
40examinations, in a proficiency testing program approved by the
P10 1department or by CMS, to the same extent as required by CLIA
2in Subpart H (commencing with Section 493.801) of Title 42 of
3the Code of Federal Regulations. This requirement does not
4prohibit a clinical laboratory from performing clinical laboratory
5tests or
examinations in a specialty or subspecialty for which there
6is no department or CMS approved proficiency testing program.
7(B) Each clinical laboratory shall authorize its proficiency test
8results to be reported to the department in an electronic format that
9is compatible with the department’s proficiency testing data
10monitoring system and shall authorize the release of proficiency
11tests results to the public to the same extent required by CLIA.
12(b) Each clinical laboratory shall be conducted, maintained, and
13operated without injury to the public health.
14(c) The department shall conduct an investigation of complaints
15received concerning a clinical laboratory that may include an
16inspection of the laboratory.
17(d) (1) Each clinical
laboratory shall perform all clinical
18laboratory tests or examinations classified as waived under CLIA
19in conformity with the manufacturer’s instructions.
20(2) Except for those clinical laboratories performing only tests
21or examinations classified as waived under CLIA, each clinical
22laboratory shall establish and maintain all of the following:
23(A) A patient test management system that meets the standards
24of CLIA in Subpart J (commencing with Section 493.1100) of
25Title 42 of the Code of Federal Regulations.
26(B) A quality control program that meets the requirements of
27CLIA in Subpart K (commencing with Section 493.1200) of Title
2842 of the Code of Federal Regulations as in effect on January 1,
292015, and that may include the clinical laboratory’s use of an
30Individualized Quality Control Plan, as incorporated into Appendix
31
C of the State Operations Manual adopted by the federal Centers
32for Medicare and Medicaid Services (CMS).
33(C) A comprehensive quality assurance program that meets the
34standards of CLIA in Subpart P (commencing with Section
35493.1701) of Title 42 of the Code of Federal Regulations.
Section 1223 of the Business and Professions Code is
37repealed.
begin insertSection 1223 is added to the end insertbegin insertBusiness and Professions
39Codeend insertbegin insert, to read:end insert
Clinical laboratories shall choose to be overseen by the
2department, pursuant to subdivision (a), or may seek certification
3of deemed status by an accrediting organization approved under
4CLIA, pursuant to subdivision (b). The accrediting organization
5may issue certificates of deemed status and may provide continued
6oversight to ensure compliance with state law.
7
(a) The department shall monitor, inspect, and investigate all
8clinical laboratories that are not accredited by an organization
9approved under CLIA for compliance with state standards that
10are in excess of federal standards.
11
(b) (1) A clinical laboratory that is accredited by an
12organization approved under CLIA shall be deemed
to meet all
13state standards and shall not require monitoring, inspection, or
14investigation pursuant to subdivision (a), but may be subject to
15investigation by the department under other provisions of law.
16
(2) An accrediting organization shall provide the department
17with documentation of approval by the federal Centers for
18Medicare & Medicaid Services as an accrediting body under CLIA,
19a detailed comparison of the individual accreditation or approval
20requirements, with the comparable California condition-level
21requirements, including standards that are in excess of federal
22law, and a list of all of the clinical laboratories that operate in
23California, including the CLIA number and the expiration date of
24their accreditation, as applicable.
25
(c) The department may concentrate its resources on upholding
26personnel standards.
Section 1227 of the Business and Professions Code is
29repealed.
begin insertSection 1227 is added to the end insertbegin insertBusiness and Professions
31Codeend insertbegin insert, to read:end insert
The department shall post on its Internet Web site a
33comprehensive list of the differences between state and CLIA.
Section 1241.1 of the Business and Professions Code
36 is repealed.
Section 1244 of the Business and Professions Code
39 is amended to read:
This chapter does not restrict, limit, or prevent a program
2of nondiagnostic general health assessment provided that:
3(1) The program complies with the requirements of CLIA for
4waived testing.
5(2) The purpose of the program is to screen asymptomatic
6individuals for chronic health disorders and to refer individuals to
7licensed sources of care as indicated.
8(3) The program does not test for human immunodeficiency
9virus or any reportable disease or condition identified in Section
10120130 of the Health and Safety Code or the regulations adopted
11under that section.
12(4) The program utilizes only those devices that comply with
13all of the following:
14(A) Meet all applicable state and federal performance standards
15pursuant to Section 111245 of the Health and Safety Code.
16(B) Are not adulterated as specified in Article 2 (commencing
17with Section 111250) of Chapter 6 of Part 5 of Division 104 of
18the Health and Safety Code.
19(C) Are not misbranded as specified in Article 3 (commencing
20with Section 111330) of Chapter 6 of Part 5 of Division 104 of
21the Health and Safety Code.
22(D) Are not new devices unless they meet the requirements of
23Section 111550 of the Health and Safety Code.
24(E) Are approved as waived tests and are used according to the
25
manufacturer’s instructions.
26(5) Blood collection is performed by skin puncture only.
27(6) Testing of a urine specimen is performed by the dipstick
28method only.
29(7) Testing is performed on site and reported directly to the
30person requesting the test.
31(8) The program maintains a supervisory committee consisting
32of, at a minimum, a licensed physician and surgeon and a clinical
33laboratory scientist licensed pursuant to this code.
34(9) The supervisory committee for the program adopts written
35protocols that shall be followed in the program and that shall
36contain all of the following:
37(A) Provision of written information to
individuals to be
38assessed that shall include, but not be limited to, the following:
39(i) The potential risks and benefits of assessment procedures to
40be performed in the program.
P13 1(ii) The limitations, including the nondiagnostic nature, of
2assessment examinations of biological specimens performed in
3the program.
4(iii) Information regarding the risk factors or markers targeted
5by the program.
6(iv) The need for followup with licensed sources of care for
7confirmation, diagnosis, and treatment as appropriate.
8(B) Proper use of each device utilized in the program including
9the operation of analyzers, maintenance of equipment and supplies,
10and performance of quality control procedures including
the
11determination of both accuracy and reproducibility of
12measurements in accordance with instructions provided by the
13manufacturer of the assessment device used.
14(C) Proper procedures to be employed when collecting blood,
15if blood specimens are to be obtained.
16(D) Proper procedures to be employed in handling and disposing
17of all biological specimens to be obtained and material
18contaminated by those biological specimens. These procedures
19shall comply with all county and city ordinances for medical waste
20management and blood-borne pathogen control that apply to the
21location where the program operates.
22(E) Proper procedures to be employed in response to fainting,
23excessive bleeding, or other medical emergencies.
24(F) Documentation that the testing
personnel are following the
25instructions of the instrument’s manufacturer, are trained in the
26performance of the test, and are competent to perform the testing
27without supervision.
28(G) Reporting of assessment results to the individual being
29assessed.
30(H) Referral and followup to licensed sources of care as
31indicated.
32(10) (a) The written protocols adopted by the supervisory
33committee shall be maintained for at least one year following
34completion of the assessment program, during which period they
35shall be subject to review by department personnel and the local
36health officer or his or her designee, including the public health
37laboratory director.
38(b) If skin puncture to obtain a blood specimen is to be
39performed in a program of
nondiagnostic general health
P14 1assessment, the individual performing the skin puncture shall be
2authorized to perform skin puncture under this chapter.
3(c) A program of nondiagnostic general health assessment that
4fails to meet the requirements set forth in subdivisions (a) and (b)
5shall not operate.
6(d) For purposes of this section, “skin puncture” means the
7collection of a blood specimen by the finger prick method only
8and does not include venipuncture, arterial puncture, or any other
9procedure for obtaining a blood specimen.
10(e) This chapter does not prohibit a licensed clinical laboratory
11from operating a program of nondiagnostic general health
12assessment provided that the clinical laboratory complies with the
13requirements of this section.
14(f) A
program for a health fair providing diagnostic or screening
15tests is not a nondiagnostic general health assessment program if
16all of the requirements of this chapter are met, and the laboratory
17performing the testing is licensed by federal law or is operating
18with a waiver for the applicable procedures. For a test that is not
19authorized for self-ordering pursuant to Section 1246.5 and that
20is not for a nondiagnostic general health assessment pursuant to
21this section, the clinical laboratory participating in the health fair
22shall assure that the test is ordered onsite only by a person licensed
23under this division who is authorized under his or her scope of
24practice to order the test or by a person authorized by that licensee.
25The results of a test performed at a health fair shall be provided
26to the test subject along with an explanation of the results.
Section 1246.5 of the Business and Professions Code
29 is amended to read:
(a) Notwithstanding any other law, a person may
31request, and a licensed clinical laboratory or public health
32laboratory may perform, the laboratory tests specified in this
33section. A registered clinical laboratory may perform the laboratory
34tests specified in this section if the test is subject to a certificate
35of waiver under CLIA. A program for nondiagnostic general health
36assessment that includes a laboratory test specified in this section
37shall comply with the provisions of Section 1244. The results from
38any test may be provided directly to the person requesting the test
39if the test is on or for his or her own body. These test results shall
40be provided in a manner that presents clear information and that
P15 1identifies results indicating the need for referral to a physician and
2
surgeon.
3(b) The tests that may be conducted pursuant to this section are:
4pregnancy, glucose level, cholesterol, occult blood, and any other
5test for which there is a test for a particular analyte approved by
6the federal Food and Drug Administration for sale to the public
7without a prescription in the form of an over-the-counter test kit.
8A test approved only as an over-the-counter collection device may
9not be conducted pursuant to this section.
Section 1265 of the Business and Professions Code
12 is repealed.
Section 1265.1 of the Business and Professions Code
15 is repealed.
Section 1266 of the Business and Professions Code
18 is repealed.
Section 1267 of the Business and Professions Code
21 is repealed.
Section 1268 of the Business and Professions Code
24 is repealed.
Section 1271.1 of the Business and Professions Code
27 is amended to read:
(a) A clinical laboratory that provides cytology
29services shall, if the laboratory ceases operation, preserve records,
30reports, cytology slides, and cell blocks as prescribed in subdivision
31(g) of Section 1271 and Section 1274.
32(b) A person injured as a result of the laboratory’s abandonment
33of records may bring an action in a court of competent jurisdiction
34for the amount of damages suffered as a result. If the laboratory
35was a corporation or partnership that has been dissolved, the person
36injured may bring an action against that corporation’s or
37partnership’s principal officers of record at the time of the
38dissolution.
39(c) For purposes of this section, the
following definitions shall
40apply:
P16 1(1) “Abandonment of records” means violating subdivision (a)
2and thereby leaving patients and physicians and surgeons without
3access to information to which they are entitled pursuant to this
4chapter.
5(2) “Principal officers” means:
6(A) In the case of a partnership other than a limited partnership,
7any partner.
8(B) In the case of a limited partnership, any general partner, as
9defined in Section 15904.02 of the Corporations Code.
10(C) In the case of a corporation, the chairperson of the board,
11the chief executive officer, and the president of the corporation.
Section 1272 of the Business and Professions Code
14 is amended to read:
A clinical laboratory shall participate in a CLIA-approved
16proficiency testing program and demonstrate satisfactory
17performance in all of the laboratory specialities that include tests
18performed in the laboratory. Proficiency shall be tested in the
19following specialties: microbiology, serology, clinical chemistry,
20hematology, cytology, and immunohematology.
begin insertSection 1272.1 is added to the end insertbegin insertBusiness and
22Professions Codeend insertbegin insert, to read:end insert
(a) If a clinical laboratory ceases operations, the
24laboratory owners, or delegated representatives of the owners,
25and the laboratory directors shall notify the department of this
26fact, in writing, within 30 calendar days from the date a clinical
27laboratory ceases operation. For purposes of this section, a
28laboratory ceases operations when it suspends the performance
29of all clinical laboratory tests or examinations for 30 calendar
30days at the location for which the clinical laboratory is licensed
31or registered.
32
(b) (1) Notwithstanding any other law, owners and laboratory
33directors of all clinical laboratories, including those laboratories
34that cease operations, shall preserve medical records and
35
laboratory records, as defined in this section, for three years from
36the date of testing, examination, or purchase, unless a longer
37retention period is required by any other law, and shall maintain
38an ability to provide those records when requested by the
39department or any duly authorized representative of the
40department.
P17 1
(2) For purposes of this subdivision, “medical records” means
2the test requisition or test authorization, or the patient’s chart or
3medical record if used as the test requisition, the final and
4preliminary test or examination result, and the name of the person
5contacted if the laboratory test or examination result indicated an
6imminent life-threatening result or was of panic value.
7
(3) For purposes of this subdivision, “laboratory records”
8means records showing compliance with CLIA and this chapter
9during a laboratory’s operation that are actual or true copies,
10
either photocopies or electronically reproducible copies, of records
11for patient test management, quality control, quality assurance,
12and all invoices documenting the purchase or lease of laboratory
13equipment and test kits, reagents, or media.
14
(4) Information contained in medical records and laboratory
15records shall be confidential, and shall be disclosed only to
16authorized persons in accordance with federal, state, and local
17laws.
18
(c) The department or any person injured as a result of a
19laboratory’s abandonment or failure to retain records pursuant
20to this section may bring an action in a court of proper jurisdiction
21for any reasonable amount of damages suffered as a result thereof.
Section 1272.4 of the Business and Professions Code
24 is repealed.
Section 1272.6 of the Business and Professions Code
27 is repealed.
Section 1281 of the Business and Professions Code
30 is repealed.
Section 1300 of the Business and Professions Code
33 is amended to read:
The amount of application and license fees under this
35chapter shall be as follows:
36(a) The application fee for a histocompatibility laboratory
37director’s, clinical laboratory bioanalyst’s, clinical chemist’s,
38clinical microbiologist’s, clinical laboratory toxicologist’s, clinical
39cytogeneticist’s, or clinical genetic molecular biologist’s license
40is sixty-three dollars ($63).
P18 1(b) The annual renewal fee for a histocompatibility laboratory
2director’s, clinical laboratory bioanalyst’s, clinical chemist’s,
3clinical microbiologist’s, clinical laboratory toxicologist’s, clinical
4cytogeneticist’s, or clinical genetic molecular biologist’s license
5is sixty-three dollars ($63).
6(c) The application fee for a clinical laboratory scientist’s or
7limited clinical laboratory scientist’s license is thirty-eight dollars
8($38).
9(d) The application and annual renewal fee for a
10cytotechnologist’s license is fifty dollars ($50).
11(e) The annual renewal fee for a clinical laboratory scientist’s
12or limited clinical laboratory scientist’s license is twenty-five
13dollars ($25).
14(f) The application fee for a trainee’s license is thirteen dollars
15($13).
16(g) The annual renewal fee for a trainee’s license is eight dollars
17($8).
18(h) The application fee for a duplicate license is five dollars
19($5).
20(i) The
personnel licensing delinquency fee is equal to the annual
21renewal fee.
22(j) The director may establish a fee for examinations required
23under this chapter. The fee shall not exceed the total cost to the
24department in conducting the examination.
25(k) The state, a district, city, county, city and county, or other
26political subdivision, or a public officer or body shall be subject
27to the payment of fees established pursuant to this chapter or
28regulations adopted thereunder.
29(l) The department shall establish an application fee and a
30renewal fee for a medical laboratory technician license, the total
31fees collected not to exceed the costs of the department for the
32implementation and operation of the program licensing and
33regulating medical laboratory technicians pursuant to Section
34
1260.3.
Section 1300.1 of the Business and Professions Code
37 is repealed.
Section 1301 of the Business and Professions Code
40 is amended to read:
(a) The department shall give written notice to all
2persons licensed pursuant to Section 1260, 1260.1, 1261, 1261.5,
31262, 1264, or 1270 at least 30 days in advance of the regular
4renewal date that a renewal fee has not been paid. In addition, the
5department shall give written notice to licensed clinical laboratory
6bioanalysts or doctoral degree specialists and clinical laboratory
7scientists or limited clinical laboratory scientists by registered or
8certified mail 90 days in advance of the expiration of the fifth year
9that a renewal fee has not been paid and, if not paid before the
10expiration of the fifth year of delinquency, the licensee may be
11subject to reexamination.
12(b) If the renewal fee is not paid for five or more years, the
13department may require an
examination before reinstating the
14license, except that an examination shall not be required as a
15condition for reinstatement if the original license was issued
16without an examination. An examination shall not be required for
17reinstatement if the license was forfeited solely by reason of
18nonpayment of the renewal fee if the nonpayment was for less than
19five years.
20(c) If the license is not renewed within 60 days after its
21expiration, the licensee, as a condition precedent to renewal, shall
22pay the delinquency fee identified in subdivision (i) of Section
231300, in addition to the renewal fee in effect on the last preceding
24regular renewal date. Payment of the delinquency fee is not
25necessary if, within 60 days of the license expiration date, the
26licensee files an application for inactive status.
Section 1310 of the Business and Professions Code
29 is repealed.
begin insertSection 1310 is added to the end insertbegin insertBusiness and Professions
31Codeend insertbegin insert, to read:end insert
(a) If the department determines that a clinical
33laboratory does not substantially meet the requirements of this
34chapter or federal law, the department may impose any of the
35following:
36
(1) Directed plans of correction, as defined under CLIA.
37
(2) Civil money penalties in an amount ranging from fifty dollars
38($50) to three thousand dollars ($3,000) per day of noncompliance,
39or per violation, for a condition-level deficiency that does not pose
40immediate jeopardy, to an amount ranging from three thousand
P20 1fifty dollars ($3,050) to ten thousand dollars ($10,000) per day of
2noncompliance, or per violation, for a condition-level deficiency
3that poses immediate jeopardy, but only after notice
and an
4opportunity to respond in accordance with Section 100171 of the
5Health and Safety Code, and consideration of facts enumerated
6in CLIA in Section 493.1834 of Title 42 of the Code of Federal
7Regulations.
8
(3) Civil money penalties in an amount ranging from fifty dollars
9($50) to three thousand dollars ($3,000) per day of noncompliance,
10or per violation, for failure to comply with disease reporting
11requirements, but only after notice and an opportunity to respond
12in accordance with Section 100171 of the Health and Safety Code.
13
(4) Onsite monitoring, as defined under CLIA, and payment for
14the costs of onsite monitoring.
15
(5) Any combination of the actions described in paragraphs (1)
16to (4), inclusive.
17
(b) The department or its agents may enter and
inspect a clinical
18laboratory at any time to enforce state laws and regulations,
19including, but not limited to, state standards that are more stringent
20than federal standards.
Section 1320 of the Business and Professions Code
23 is amended to read:
The department may deny, suspend, or revoke a license
25issued pursuant to this chapter for any of the following reasons:
26(a) Conduct involving moral turpitude or dishonest reporting
27of tests.
28(b) Violation by the applicant or licensee of this chapter or a
29rule or regulation adopted pursuant thereto.
30(c) Aiding, abetting, or permitting the violation of this chapter,
31the rules or regulations adopted pursuant to this chapter, or the
32Medical Practice Act (Chapter 5 (commencing with Section 2000)
33of Division 2).
34(d) Permitting a licensed trainee to perform tests
or procure
35specimens unless under direct and responsible supervision.
36(e) Violation of any provision of this code governing the practice
37of medicine and surgery.
38(f) Proof that an applicant or licensee has made false statements
39in any material regard on the application for a license or renewal
40issued pursuant to this chapter.
P21 1(g) Conduct inimical to the public health, morals, welfare, or
2safety of the people of the State of California in the provision of
3services for which a license is issued pursuant to this chapter.
4(h) Proof that the applicant or licensee has used a degree or
5certificate as a means of qualifying for licensure that has been
6purchased or procured by barter or by any unlawful means or
7obtained from an institution that, at the time the
degree, certificate,
8or title was obtained, was not recognized or accredited by the
9department of education of the state where the institution is or was
10located to give training in the field of study in which the degree,
11certificate, or title is claimed.
12(i) Violation of any of the prenatal laws or regulations pertaining
13thereto in Chapter 2 (commencing with Section 120675) of Part
143 of Division 105 of the Health and Safety Code and Article 1
15(commencing with Section 1125) of Group 4 of Subchapter 1 of
16Chapter 2 of Part 1 of Title 17 of the California Code of
17Regulations.
18(j) Knowingly accepting an assignment for clinical laboratory
19tests or specimens from, and the rendering of a report thereon to,
20persons not authorized by law to submit those specimens or
21assignments.
22(k) Rendering a report on clinical laboratory
work actually
23performed in another clinical laboratory without designating clearly
24the name and address of the laboratory in which the test was
25performed.
26(l) Conviction of a felony or misdemeanor involving moral
27turpitude under the laws of any state or of the United States arising
28out of or in connection with the practice of clinical laboratory
29technology. The record of conviction or a certified copy thereof
30shall be conclusive evidence of that conviction.
31(m) Unprofessional conduct.
32(n) The use of drugs or alcoholic beverages to the extent or in
33a manner as to be dangerous to a person licensed under this chapter,
34or any other person to the extent that use impairs the ability of the
35licensee to conduct, with safety to the public, the practice of clinical
36laboratory technology.
37(o) Misrepresentation in obtaining a license.
38(p) Performance of a clinical laboratory test or examination or
39other procedure that is not within the specialties or subspecialties,
40or category of laboratory procedures authorized by the license.
Section 1324 of the Business and Professions Code
3 is repealed.
Section 1325 of the Business and Professions Code
6 is repealed.
Section 9272 of the Food and Agricultural Code is
9amended to read:
The provisions of this chapter shall not apply (1) to
11facilities primarily engaged in the collection, preparation, testing,
12processing, storage, or distribution of human blood or blood
13products, provided the facility is licensed pursuant to Chapter 4
14(commencing with Section 1600) of Division 2 of the Health and
15Safety Code and any biologic, as defined in Section 9203, produced
16by the facility is sold or distributed only to an establishment
17licensed by this chapter or (2) to clinical laboratories whose only
18biologics are autogenous bacterins prepared at the request of
19licensed veterinarians.
Section 1206 of the Health and Safety Code is
22amended to read:
This chapter does not apply to the following:
24(a) Except with respect to the option provided with regard to
25surgical clinics in paragraph (1) of subdivision (b) of Section 1204
26and, further, with respect to specialty clinics specified in paragraph
27(2) of subdivision (b) of Section 1204, a place or establishment
28owned or leased and operated as a clinic or office by one or more
29licensed health care practitioners and used as an office for the
30practice of their profession, within the scope of their license,
31regardless of the name used publicly to identify the place or
32establishment.
33(b) A clinic directly conducted, maintained, or operated by the
34United States or by any of its departments, officers, or agencies,
35and any primary
care clinic specified in subdivision (a) of Section
361204 that is directly conducted, maintained, or operated by this
37state or by any of its political subdivisions or districts, or by any
38city. Nothing in this subdivision precludes the department from
39adopting regulations that utilize clinic licensing standards as
40eligibility criteria for participation in programs funded wholly or
P23 1partially under Title XVIII or XIX of the federal Social Security
2Act.
3(c) (1) A clinic conducted, maintained, or operated by a
4federally recognized Indian tribe or tribal organization, as defined
5in Section 450 or 1603 of Title 25 of the United States Code, that
6is located on land recognized as tribal land by the federal
7government.
8(2) A clinic conducted, maintained, or operated by a federally
9recognized Indian tribe or tribal organization, as defined in Section
10450 or 1603 of
Title 25 of the United States Code, under a contract
11with the United States pursuant to the Indian Self-Determination
12and Education Assistance Act (Public Law 93-638), regardless of
13the location of the clinic, except that if the clinic chooses to apply
14to the State Department of Public Health for a state facility license,
15then the State Department of Public Health will retain authority
16to regulate that clinic as a primary care clinic as defined by
17subdivision (a) of Section 1204.
18(d) Clinics conducted, operated, or maintained as outpatient
19departments of hospitals.
20(e) A facility licensed as a health facility under Chapter 2
21(commencing with Section 1250).
22(f) A freestanding clinical or pathological laboratory.
23(g) A clinic operated by, or affiliated
with, an institution of
24learning that teaches a recognized healing art and is approved by
25the state board or commission vested with responsibility for
26regulation of the practice of that healing art.
27(h) A clinic that is operated by a primary care community or
28free clinic and that is operated on separate premises from the
29licensed clinic and is only open for limited services of no more
30than 30 hours a week. An intermittent clinic, as described in this
31subdivision, shall meet all other requirements of law, including
32administrative regulations and requirements, pertaining to fire and
33life safety.
34(i) The offices of physicians in group practice who provide a
35preponderance of their services to members of a comprehensive
36group practice prepayment health care service plan subject to
37Chapter 2.2 (commencing with Section 1340).
38(j) Student health centers operated by public institutions of
39higher education.
P24 1(k) Nonprofit speech and hearing centers, as defined in Section
21201.5. A nonprofit speech and hearing clinic desiring an
3exemption under this subdivision shall apply to the director, who
4shall grant the exemption to any facility meeting the criteria of
5Section 1201.5. Notwithstanding the licensure exemption contained
6in this subdivision, a nonprofit speech and hearing center shall be
7deemed to be an organized outpatient clinic for purposes of
8qualifying for reimbursement as a rehabilitation center under the
9Medi-Cal Act (Chapter 7 (commencing with Section 14000) of
10Part 3 of Division 9 of the Welfare and Institutions Code).
11(l) A clinic operated by a nonprofit corporation exempt from
12federal income taxation under paragraph (3) of subsection (c) of
13Section 501 of the Internal
Revenue Code of 1954, as amended,
14or a statutory successor thereof, that conducts medical research
15and health education and provides health care to its patients through
16a group of 40 or more physicians and surgeons, who are
17independent contractors representing not less than 10
18board-certified specialties, and not less than two-thirds of whom
19practice on a full-time basis at the clinic.
20(m) A clinic, limited to in vivo diagnostic services by magnetic
21resonance imaging functions or radiological services under the
22direct and immediate supervision of a physician and surgeon who
23is licensed to practice in California. This shall not be construed to
24permit cardiac catheterization or any treatment modality in these
25clinics.
26(n) A clinic operated by an employer or jointly by two or more
27employers for their employees only, or by a group of employees,
28or jointly by employees and employers,
without profit to the
29operators thereof or to any other person, for the prevention and
30treatment of accidental injuries to, and the care of the health of,
31the employees comprising the group.
32(o) A community mental health center, as defined in Section
335667 of the Welfare and Institutions Code.
34(p) (1) A clinic operated by a nonprofit corporation exempt
35from federal income taxation under paragraph (3) of subsection
36(c) of Section 501 of the Internal Revenue Code of 1954, as
37amended, or a statutory successor thereof, as an entity organized
38and operated exclusively for scientific and charitable purposes and
39that satisfied all of the following requirements on or before January
401, 2005:
P25 1(A) Commenced conducting medical research on or before
2January 1, 1982, and continues to conduct medical
research.
3(B) Conducted research in, among other areas, prostatic cancer,
4cardiovascular disease, electronic neural prosthetic devices,
5biological effects and medical uses of lasers, and human magnetic
6resonance imaging and spectroscopy.
7(C) Sponsored publication of at least 200 medical research
8articles in peer-reviewed publications.
9(D) Received grants and contracts from the National Institutes
10of Health.
11(E) Held and licensed patents on medical technology.
12(F) Received charitable contributions and bequests totaling at
13least five million dollars ($5,000,000).
14(G) Provides health care services to patients only:
15(i) In conjunction with research being conducted on procedures
16or applications not approved or only partially approved for payment
17(I) under the Medicare program pursuant to Section 1359y(a)(1)(A)
18of Title 42 of the United States Code, or (II) by a health care service
19plan registered under Chapter 2.2 (commencing with Section 1340),
20or a disability insurer regulated under Chapter 1 (commencing
21with Section 10110) of Part 2 of Division 2 of the Insurance Code;
22provided that services may be provided by the clinic for an
23additional period of up to three years following the approvals, but
24only to the extent necessary to maintain clinical expertise in the
25procedure or application for purposes of actively providing training
26in the procedure or application for physicians and surgeons
27unrelated to the clinic.
28(ii) Through physicians and surgeons who, in the aggregate,
29devote no more than 30
percent of their professional time for the
30entity operating the clinic, on an annual basis, to direct patient care
31activities for which charges for professional services are paid.
32(H) Makes available to the public the general results of its
33research activities on at least an annual basis, subject to good faith
34protection of proprietary rights in its intellectual property.
35(I) Is a freestanding clinic, whose operations under this
36subdivision are not conducted in conjunction with any affiliated
37or associated health clinic or facility defined under this division,
38except a clinic exempt from licensure under subdivision (m). For
39purposes of this subparagraph, a freestanding clinic is defined as
40“affiliated” only if it directly, or indirectly through one or more
P26 1intermediaries, controls, or is controlled by, or is under common
2control with, a clinic or health facility defined under this
division,
3except a clinic exempt from licensure under subdivision (m). For
4purposes of this subparagraph, a freestanding clinic is defined as
5“associated” only if more than 20 percent of the directors or trustees
6of the clinic are also the directors or trustees of any individual
7clinic or health facility defined under this division, except a clinic
8exempt from licensure under subdivision (m). Any activity by a
9clinic under this subdivision in connection with an affiliated or
10associated entity shall fully comply with the requirements of this
11subdivision. This subparagraph shall not apply to agreements
12between a clinic and any entity for purposes of coordinating
13medical research.
14(2) By January 1, 2007, and every five years thereafter, the
15Legislature shall receive a report from each clinic meeting the
16criteria of this subdivision and any other interested party
17concerning the operation of the clinic’s activities. The report shall
18include, but not
be limited to, an evaluation of how the clinic
19impacted competition in the relevant health care market, and a
20detailed description of the clinic’s research results and the level
21of acceptance by the payer community of the procedures performed
22at the clinic. The report shall also include a description of
23procedures performed both in clinics governed by this subdivision
24and those performed in other settings. The cost of preparing the
25reports shall be borne by the clinics that are required to submit
26them to the Legislature pursuant to this paragraph.
Section 1600.3 of the Health and Safety Code is
29amended to read:
“Blood bank depository” means a place other than a
31blood bank where human whole blood and human whole blood
32derivatives specified by regulation are stored and held for
33transfusion. Blood bank depositories shall be clinical laboratories,
34licensed in accordance with the provisions of federal law, or other
35places where services essentially equivalent are maintained, as
36determined by the department.
Section 14043.27 of the Welfare and Institutions
39Code is amended to read:
(a) If an applicant or provider is granted provisional
2provider status or preferred provisional provider status pursuant
3to Section 14043.26 and, if at any time during the provisional
4provider status period or preferred provisional provider status
5period, the department conducts any announced or unannounced
6visits or any additional inspections or reviews pursuant to this
7chapter or Chapter 8 (commencing with Section 14200), or the
8regulations adopted thereunder, or pursuant to Section 100185.5
9of the Health and Safety Code, and discovers or otherwise
10determines the existence of any ground to deactivate the provider’s
11number and business addresses or suspend the provider from the
12Medi-Cal program pursuant to this chapter or Chapter 8
13(commencing with Section 14200), or the regulations
adopted
14thereunder, or pursuant to Section 100185.5 of the Health and
15Safety Code, or if any of the circumstances listed in subdivision
16(c) occur, the department shall terminate the provisional provider
17status or preferred provisional provider status of the provider,
18regardless of whether the period of time for which the provisional
19provider status or preferred provisional provider status was granted
20under Section 14043.26 has elapsed.
21(b) Termination of provisional provider status or preferred
22provisional provider status shall include deactivation of the
23provider’s number, including all business addresses used by the
24provider to obtain reimbursement from the Medi-Cal program and
25removal of the provider from enrollment in the Medi-Cal program,
26except where the termination is based upon a ground related solely
27to a specific location for which provisional provider status was
28granted. Termination of provisional provider status based upon
29grounds
related solely to a specific location may include failure
30to have an established place of business, failure to possess the
31business or zoning permits or other approvals necessary to operate
32a business, or failure to possess the appropriate licenses, permits,
33or certificates necessary for the provider of service category or
34subcategory identified by the provider in its application package.
35Where the grounds relate solely to a specific location, the
36termination of provisional provider status shall include only
37deactivation of the specific locations that the grounds apply to and
38shall include removal of the provider from enrollment in the
39Medi-Cal program only if, after deactivation of the specific
P28 1locations, the provider does not have any business address that is
2not deactivated.
3(c) The following circumstances are grounds for termination of
4provisional provider status or preferred provisional provider status:
5(1) The provider, persons with an ownership or control interest
6in the provider, or persons who are directors, officers, or managing
7employees of the provider have been convicted of any felony, or
8convicted of any misdemeanor involving fraud or abuse in any
9government program, related to neglect or abuse of a patient in
10connection with the delivery of a health care item or service, or in
11connection with the interference with, or obstruction of, any
12investigation into health care related fraud or abuse, or have been
13found liable for fraud or abuse in any civil proceeding, or have
14entered into a settlement in lieu of conviction for fraud or abuse
15in any government program within 10 years of the date of the
16application package.
17(2) There is a material discrepancy in the information provided
18to the department, or with the requirements to be enrolled, that is
19discovered after provisional
provider status or preferred provisional
20provider status has been granted and that cannot be corrected
21because the discrepancy occurred in the past.
22(3) The provider has provided material information that was
23false or misleading at the time it was provided.
24(4) The provider failed to have an established place of business
25at the business address for which the application package was
26submitted at the time of any onsite inspection, announced or
27unannounced visit, or any additional inspection or review
28conducted pursuant to this article or a statute or regulation
29governing the Medi-Cal program, unless the practice of the
30provider’s profession or delivery of services, goods, supplies, or
31merchandise is such that services, goods, supplies, or merchandise
32are rendered or delivered at locations other than the business
33address and this practice or delivery of services, goods, supplies,
34or
merchandise has been disclosed in the application package
35approved by the department when the provisional provider status
36or preferred provisional provider status was granted.
37(5) The provider meets the definition of a clinic under Section
381200 of the Health and Safety Code, but is not licensed as a clinic
39pursuant to Chapter 1 (commencing with Section 1200) of Division
402 of the Health and Safety Code and fails to meet the requirements
P29 1to qualify for at least one exemption pursuant to Section 1206 or
21206.1 of the Health and Safety Code.
3(6) The provider performs clinical laboratory tests or
4examinations, but it or its personnel do not meet CLIA, and the
5regulations adopted thereunder, do not possess valid CLIA
6certificates, or are not exempt pursuant to Section 1241 of the
7Business and Professions Code.
8(7) The provider fails to possess either of the following:
9(A) The appropriate licenses, permits, certificates, or other
10approvals needed to practice the profession or occupation, or
11provide the services, goods, supplies, or merchandise the provider
12identified in the application package approved by the department
13when the provisional provider status or preferred provisional
14provider status was granted and for the location for which the
15application was submitted.
16(B) The business or zoning permits or other approvals necessary
17to operate a business at the location identified in its application
18package approved by the department when the provisional provider
19status or preferred provisional provider status was granted.
20(8) The provider, or if the provider is a clinic, group, partnership,
21corporation, or other association, any
officer, director, or
22shareholder with a 10 percent or greater interest in that
23organization, commits two or more violations of the federal or
24state statutes or regulations governing the Medi-Cal program, and
25the violations demonstrate a pattern or practice of fraud, abuse, or
26provision of unnecessary or substandard medical services.
27(9) The provider commits any violation of a federal or state
28statute or regulation governing the Medi-Cal program or of a statute
29or regulation governing the provider’s profession or occupation
30and the violation represents a threat of immediate jeopardy or
31significant harm to any Medi-Cal beneficiary or to the public
32welfare.
33(10) The provider submits claims for payment that subject a
34provider to suspension under Section 14043.61.
35(11) The provider submits claims for payment for
services,
36goods, supplies, or merchandise rendered at a location other than
37the business address or addresses listed on the application for
38enrollment, unless the practice of the provider’s profession or
39delivery of services, goods, supplies, or merchandise is such that
40services, goods, supplies, or merchandise are rendered or delivered
P30 1at locations other than the business address and this practice or
2delivery of services, goods, supplies, or merchandise has been
3disclosed in the application package approved by the department
4when the provisional provider status was granted.
5(12) The provider has not paid its fine, or has a debt due and
6owing, including overpayments and penalty assessments, to any
7federal, state, or local government entity that relates to Medicare,
8medicaid, Medi-Cal, or any other federal or state health care
9program, and has not made satisfactory arrangements to fulfill the
10obligation or otherwise been excused by legal process
from
11fulfilling the obligation.
12(d) If, during a provisional provider status period or a preferred
13provisional provider status period, the department conducts any
14announced or unannounced visits or any additional inspections or
15reviews pursuant to this chapter or Chapter 8 (commencing with
16Section 14200), or the regulations adopted thereunder, and
17commences an investigation for fraud or abuse, or discovers or
18otherwise determines that the provider is under investigation for
19fraud or abuse by any other state, local, or federal government law
20enforcement agency, the provider shall be subject to termination
21of provisional provider status or preferred provisional provider
22status, regardless of whether the period of time for which the
23provisional provider status or preferred provisional provider status
24was granted under Section 14043.26 has elapsed.
25(e) A provider whose provisional
provider status or preferred
26provisional provider status has been terminated pursuant to this
27section may appeal the termination in accordance with Section
2814043.65.
29(f) Any department-recovered fine or debt due and owing,
30including overpayments, that are subsequently determined to have
31been erroneously collected shall be promptly refunded to the
32provider, together with interest paid in accordance with subdivision
33(e) of Section 14171 and Section 14172.5.
O
98